Effects of remazolam besylate versus propofol on circulatory system in patients undergoing cardiac surgery: a single-center, prospective, randomized, single-blind controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200055632

Enrollment

Unknown

Registered

2022-01-15

Start date

2022-01-14

Completion date

Unknown

Last updated

2023-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiac surgery

Interventions

Group 1 :Propofol was injected intravenously at 1.5-2.0 mg/kg during induction, and the infusion was completed within 2.5 min

Group 2:Remazolam besylate was intravenously pumped at 6 mg/kg/h during induction, and the infusion was completed within 2.5 min

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged > 18 years, gender is not limited; 2. Body mass index (BMI) 18.5-30 kg/m2; 3. ASA II-III level; 4. Patients undergoing coronary artery bypass grafting or valve surgery under elective general anesthesia; 5. Voluntarily participated and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients who are resistant or allergic to benzodiazepines or other anesthetics; 2. Patients with myasthenia gravis; 3. Preoperative liver and kidney functions (ALT, AST, BUN, Cr) were significantly increased; 4. Participated in other drug trials within three months.

Design outcomes

Primary

Measure	Time frame
Changes in sublingual microcirculation;	—

Countries

China

Contacts

Public ContactLin Hongqi

Fuwaihua Central Vascular Hospital

lhq9988@126.com+86 13523583033

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026